Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 5:01 pm Sale | 13G | Gracell Biotechnologies Inc. GRCL | RA CAPITAL MANAGEMENT L.P. | 48,600,221 9.990% | -79 (-0.00%) | View |
| 2024-02-14 08:20 am Sale | 13G | Gracell Biotechnologies Inc. GRCL | William Cao Wei | 77,141,530 15.900% | -18,004,855 (-18.92%) | View |
| 2024-02-14 08:00 am Purchase | 13G | Gracell Biotechnologies Inc. GRCL | Sio Capital Management LLC | 25,007,900 5.200% | 25,007,900 (New Position) | View |
| 2024-02-13 5:26 pm Unchanged | 13G | Gracell Biotechnologies Inc. GRCL | LAV Biosciences Fund V L.P. | 25,406,680 5.300% | 0 (Unchanged) | View |
| 2024-02-13 5:00 pm Unchanged | 13G | Gracell Biotechnologies Inc. GRCL | Vivo Opportunity Fund Holdings L.P. | 38,152,030 7.700% | 0 (Unchanged) | View |
| 2023-10-19 08:10 am Sale | 13G | Gracell Biotechnologies Inc. GRCL | Temasek Holdings (Private) Ltd | 47,944,317 9.990% | -1,565,385 (-3.16%) | View |
| 2023-08-21 4:30 pm Purchase | 13G | Gracell Biotechnologies Inc. GRCL | RA CAPITAL MANAGEMENT L.P. | 48,600,300 9.990% | 48,600,300 (New Position) | View |
| 2023-08-18 4:56 pm Purchase | 13G | Gracell Biotechnologies Inc. GRCL | Vivo Opportunity Fund Holdings L.P. | 38,152,030 7.800% | 38,152,030 (New Position) | View |
| 2023-08-11 4:23 pm Purchase | 13D | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 7,641,531 8.000% | 57,955 (+0.76%) | View |
| 2023-03-31 4:48 pm Purchase | 13D | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 7,583,576 11.200% | 1,612,904 (+27.01%) | View |
| 2023-03-08 2:01 pm Sale | 13G | Gracell Biotechnologies Inc. GRCL | BlackRock Inc. BLK | 5,381,384 4.500% | -3,767,923 (-41.18%) | View |
| 2023-02-14 4:20 pm Unchanged | 13G | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 5,970,672 8.800% | 0 (Unchanged) | View |
| 2023-02-14 12:03 pm Sale | 13G | Gracell Biotechnologies Inc. GRCL | Frazier Life Sciences Public Fund L.P. | 0 0.000% | -17,104,865 (Position Closed) | View |
| 2023-02-13 3:54 pm Sale | 13G | Gracell Biotechnologies Inc. GRCL | Capital International Investors | 16,200,000 4.800% | -4,118,820 (-20.27%) | View |
| 2023-02-07 4:00 pm Purchase | 13G | Gracell Biotechnologies Inc. GRCL | William Cao Wei | 95,146,385 26.900% | 1,914,845 (+2.05%) | View |
| 2023-02-06 2:36 pm Sale | 13G | Gracell Biotechnologies Inc. GRCL | WELLINGTON MANAGEMENT GROUP LLP | 0 0.000% | -21,460,705 (Position Closed) | View |
| 2023-02-03 12:10 pm Purchase | 13G | Gracell Biotechnologies Inc. GRCL | BlackRock Inc. BLK | 4,887,820 7.200% | 4,887,820 (New Position) | View |
| 2022-03-17 12:42 pm Purchase | 13G | Gracell Biotechnologies Inc. GRCL | Frazier Life Sciences Public Fund L.P. | 17,104,865 5.100% | 17,104,865 (New Position) | View |
| 2022-02-14 2:53 pm Purchase | 13G | Gracell Biotechnologies Inc. GRCL | William Cao Wei | 93,231,540 26.900% | 93,231,540 (New Position) | View |
| 2022-02-11 4:23 pm Sale | 13G | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 5,970,672 8.900% | -23,882,692 (-80.00%) | View |